
Overview
Science services leader's Q4 revenue grew 7%, beating analyst expectations
Adjusted EPS for Q4 beat analyst expectations
Company completed acquisitions to enhance bioproduction and clinical trial capabilities
Outlook
Company will provide 2026 financial guidance during its earnings conference call
Result Drivers
INNOVATIVE PRODUCT LAUNCHES - Co launched new products like Helios MX1 Plasma Focused Ion Beam Scanning Electron Microscope, contributing to Q4 growth
STRATEGIC COLLABORATIONS - Co's collaboration with OpenAI and expansion of bioprocess design centers in Asia supported growth
CAPITAL DEPLOYMENT - Co's acquisition of Clario and other investments enhanced capabilities, driving Q4 results
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q4 Revenue | Beat | $12.22 bln | $11.95 bln (18 Analysts) |
Q4 Adjusted EPS | Beat | $6.57 | $6.45 (20 Analysts) |
Q4 EPS |
| $5.21 |
|
Q4 Adjusted Net Income | Beat | $2.48 bln | $2.43 bln (15 Analysts) |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 25 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"
Wall Street's median 12-month price target for Thermo Fisher Scientific Inc is $652.00, about 7.2% above its January 28 closing price of $608.02
The stock recently traded at 25 times the next 12-month earnings vs. a P/E of 20 three months ago
Press Release: ID:nBw1Q3rd4a
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.